Duphaston® (Dydrogesteron)
Проводит Abbott
Страница компанииMulticenter Open-Label Observational Program to Research on Predictors of Pregnancy Rate in Assisted Reproductive Technology in the Russian Population and Kazakhstan Population According to Actual International and National Guidelines (IRIS)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04249297/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–99 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1150 чел. во всех странах исследования.
- Центров в реестре: 42 в 19 городах. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 22
Критерии включения
- Female, age ≥ 18 years
- Prescribed Duphaston® according local marketing authorization and international and Russian In Vitro Fertilisation guidelines for luteal phase support as part of an Assisted Reproductive Technologies (1 tablet 3 times a day starting at the day of oocyte retrieval)
- Elective single embryo transfer in fresh cycle
- Normal ultrasound at enrollment without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technologies with respect to uterus and adnexa (incl. no hydrosalpinx or clinically relevant uterine fibroids)
- Signed the Patient Authorization for Use/Disclosure of Data
Критерии невключения
- Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study
- Acute urogenital disease
- Known allergic reactions to dydrogesterone or other progestogens products
- Any contraindication or other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions listed in the locally approved label (Instructions for the medical use of Duphaston®):
- Hypersensitivity to dydrogesterone or any of the excipients
- Diagnosed or suspected progestogen-dependent neoplasms (e.g., meningioma)
- Undiagnosed vaginal bleeding
- Hepatic impairment associated with acute or chronic, current or past liver diseases (as long as liver function tests have failed to return to normal)
- Presence or history of malignant liver tumors
- Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome
- Breastfeeding.
- Presence or history of porphyria
- Age below 18 years, since safety and efficacy in adolescents aged below 18 years have not been established
- Spontaneous abortion (miscarriage) or missed abortion in luteal-phase support as part of assisted reproductive technology
- Participation in any other clinical trial within 30 days prior to program start
- Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects in or to complete the study
- Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed)
- History of prior chemotherapy
- Usage of other progestogens except dydrogesterone
- Contraindication for pregnancy
- Refusal or inability to comply with the conditions of this program for any reason, including scheduled clinic visits and laboratory tests.
- Gestational surrogacy, oocyte or embryo donation
Источник: ClinicalTrials.gov, NCT04249297 · запись обновлена в реестре 28 декабря 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- 4-5 predictors with highest impact on the probability of clinical pregnancy as evaluated by a logistic regression model — 10 weeks
Цель исследования
Goals: To explore the association of probability of pregnancy with certain prognostic factors in patients undergoing assisted reproductive technology in Russian population according to international and national guidelines.
Где проходит
42 центра в 19 городах- Clinic 'IVF Center'
- Family Planning and Reproduction Center
- Generation NEXT
- Medical Center Altra Vita
- Medical Center MIRA
- Mother and Child Khodynka
- Mother and Child Kuntsevo
- Mother and Child Lapino
- Mother and Child Perinatal Center
- Mother and Child Savelovskaya
- Multidisciplinary Medical Center 'MAK IVF'
- NOVA Clinic, Center for Reproduction and Genetics
- Reproductive Health Clinic 'Biootpima'
- ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04249297 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.